Zepbound seems to be more effective.
"Novo’s Wegovy (like its sister diabetes drug Ozempic) targets receptors of the GLP-1 hormone, and has shown in trials to cut around 15% of people’s body weight. Meanwhile, Zepbound, which targets both the GLP-1 and GIP hormones, has shown up to 21% weight loss in trials."